Dianthus Therapeutics Announces Early GO Decision Following Interim Responder Analysis in Phase 3 CAPTIVATE Trial of Claseprubart in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Go back to Dianthus Therapeutics Announces Early GO Decision Following Interim Responder Analysis in Phase 3 CAPTIVATE Trial of Claseprubart in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)| (NASDAQ: DNTH) | Delayed: 94.34 +4.13 (4.58%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $90.21 | 52 Week High | $ | |||
| Open | $90.21 | 52 Week Low | $ | |||
| Day High | $94.70 | P/E | N/A | |||
| Day Low | $87.40 | EPS | $ | |||
| Volume | 753,184 | |||||

